Advanced clinical trials and laboratory breakthroughs are reshaping non-small cell lung cancer treatment. Studies reveal high tumor shrinkage rates with targeted drugs like zongertinib and repotrectinib, while new chemotherapy combinations show promise in halting stubborn drug resistance.
Targeting HER2 Mutations With Zongertinib
Lung cancer diagnoses account for over 49,000 cases annually in the UK, with up to 4 per cent of those instances driven by HER2 genetic mutations. These mutations occur regardless of whether a patient has a smoking history. Historically, patients with these specific alterations faced intense chemotherapy regimens accompanied by heavy side effects because targeted therapies were unavailable.
That clinical landscape shifted when a global trial evaluated zongertinib as an initial daily pill treatment for advanced lung cancer patients with HER2 mutations. According to findings presented at the European Society for Medical Oncology (ESMO) Congress in Berlin by the ICR, the trial included 74 patients aged 35 to 88 across 85 global sites. The results demonstrated that 77 per cent of patients saw their tumors shrink, with 8 per cent achieving complete disappearance and 69 per cent experiencing partial shrinkage. Overall disease control reached 96 per cent.
“The results of this study are highly significant and mean new hope for lung cancer patients with the HER2 genetic mutation.”
Professor Sanjay Popat, Professor of Thoracic Oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust
Overcoming Resistance With Gem-miR-129
While targeted therapies such as tyrosine kinase inhibitors (TKIs) help patients with epidermal growth factor receptor (EGFR) mutations, roughly half of these cancers eventually acquire resistance. To combat this hurdle, researchers at the Stony Brook Cancer Center developed a multimodal therapy combining gemcitabine with the tumor-suppressing noncoding RNA molecule miRNA-129, known as Gem-miR-129.
Designed to enter cancer cells independently without a delivery vehicle, Gem-miR-129 simultaneously shuts down three distinct oncogenic driver proteins: HMGB1, YAP1, and PBX3. Medicalxpress reported that laboratory testing in a murine non-small cell lung cancer model yielded remarkable tumor shrinkage reaching over 95 per cent. Furthermore, low-dose gemcitabine released from the agent inhibits tumor-infiltrating T regulatory cells, allowing cytotoxic CD4 and CD8 T cells to target the tumor burden more effectively.
Lead researcher Jingfang Ju noted that survival time in the treated animal models increased by many weeks, which could translate to roughly 5 to 15 additional years in human terms.
Expanding Precision Options for ROS1-Positive Tumors
The Food and Drug Administration approved repotrectinib for advanced lung cancers carrying these fusions, serving as both an initial treatment and a second-line option for patients previously treated with other ROS1 inhibitors like crizotinib or entrectinib.
Complete trial results published in the New England Journal of Medicine, as detailed by Cancer, showed that nearly 80 per cent of participants who had not previously received a ROS1-targeted drug experienced tumor shrinkage. For patients previously treated with another inhibitor, nearly 40 per cent responded. The trial, called TRIDENT-1, also demonstrated that repotrectinib successfully overcame the G2032R resistance mutation, shrinking tumors in 59 per cent of patients carrying that specific genetic change.
Patient Impact and Next-Gen Screening
Behind the clinical trial data are individual outcomes. Susan Gasson, a 74-year-old London resident treated at The Royal Marsden, experienced a cancer recurrence following initial surgery, chemotherapy, and radiotherapy for lung cancer. After joining the zongertinib trial, she has remained on the drug for over two years with minimal side effects.
Comprehensive genomic testing remains critical for identifying these molecular vulnerabilities early. Major cancer centers routinely sequence hundreds of potential gene mutations, matching patients to approved targeted medications or clinical trials before resistance takes hold.
